Blood protein may hold key to depression treatment success

NCT ID NCT02051413

Completed Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at whether certain proteins called beta-arrestins can predict how well people with major depression respond to the antidepressant venlafaxine (Effexor). Researchers followed 67 patients for three months, measuring their depression symptoms and checking blood samples for these proteins. The goal was to find a simple biological marker that could help doctors choose the right treatment from the start.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venlafaxine (extended release)
What this could lead to: If successful, this could help doctors predict which patients will benefit from venlafaxine, making depression treatment more personalized.
What could go wrong: This is a small, early-stage study (67 participants) looking at biological markers, not a treatment itself. The findings may not lead to a practical test or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER MAJOR DEPRESSIVE EPISODE

Contacts and locations

Locations

CHU de Bicetre

Le Kremlin-Bicêtre, 94275, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.